Original ArticlesTolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer
Under an Elsevier user license
open archive
Key Words
Clinical trials
Phase I
Docetaxel
Japanese
Nintedanib
Non–small-cell lung cancer
Pharmacokinetics
Cited by (0)
Funding: This work was supported by Boehringer Ingelheim.
K.K., A.S., and N.Y. are employees of Nippon Boehringer Ingelheim Co. Ltd.; R.K. is an employee of Boehringer Ingelheim Pharma GmbH & Co.; T.S. has received honoraria from Boehringer Ingelheim and is a member of their speaker bureau; all remaining authors have declared no conflict of interest.
Copyright © 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.